Enbrel's share is 44% and Herceptin's share is 37%

Expanding the influence of biosimilars in Korea

Herceptin similars increased by 28%p in 4 years

Mabthera, Avastin, and Humira similars also saw a sharp rise in market share new product addition effect.

 

The share of biosimilar products in the domestic market is rapidly expanding.

 

Enbrel biosimilars Etanercept increased its market share from 12% in 2018 to 44% last year.

 

Herceptin similars also expanded from 9% to 37% during the same period.

 

◆Eucept and Remaloce, Enbrel similar, had a 44% market share with sales of 8.1 billion won last year According to IQVIA, a pharmaceutical market research institute, on the 10th, the market for Etanercept ingredient treatment last year was 18.2 billion won.

 

Pfizer Enbrel, the original product, recorded 10.1 billion won and Enbrel biosimilar 8.1 billion won, respectively.

 

In terms of market share, original drugs accounted for 56% and biosimilars 44%.

 

The market share of biosimilars has risen significantly over the past four years.

 

In 2018, Enbrel's biosimilar market share was only 12%, but it increased by 32%p in 4 years, greatly narrowing the gap with the original.

 

LG Chem's Eucept and Samsung Bioepis' Remaloce have been released as Enbrel biosimilars.

 

Last year's sales were 4.1 billion won for Eucept and 4 billion won for Remaloce.

 

Until now, biosimilars have been evaluated as not impacting the domestic market, unlike Europe and the United States.

 

It is analyzed that recently, biosimilar products are gradually increasing their influence in Korea.

 

It is analyzed that new products have been steadily released, centered on Samsung Bioepis and Celltrion, and the preference for similar products has gradually increased in the prescription field.

 

◆Herceptin-similar market share 9% → 37%/ Avastin similar achieved 21% in 1 year Other biosimilars have also significantly increased their market share recently.

 

In the case of the trastuzumab market, the share of Herceptin biosimilars increased by 28%p in 4 years from 9% in 2018 to 37% last year.

 

Celltrion Herzuma and Samsung Bioepis Samfenet were released as Herceptin biosimilars.

 

Last year, sales were 29 billion won for Herzuma and 5.6 billion won for Samfenet.

 

Herzuma's sales increased 3.7 times in 4 years from 7.7 billion won in 2018 to last year.

 

Samfenet increased 2.5 times in 3 years from 2.2 billion won in 2019.

 

The original Herceptin sales decreased by 25% from 80 billion won in 2018 to 60 billion won last year.

 

Original's market share declined from 91% to 63%.

 

Avastin biosimilars are also rapidly expanding their market share.

 

Samsung Bioepis released the Avastin biosimilar Onbevezy in the fourth quarter of 2021.

 

Onbevezy, which recorded sales of 500 million won in the first year of its release, saw its sales skyrocket to 20.5 billion won last year.

 

As sales soared, Onbevezy's Bevacizumab market share quickly expanded to 21%.

 

Here, Celltrion Vegzelma, Alvogen Korea Alymsys, and Pfizer Korea Pharmaceutical ZIRABEV are aiming to enter the market.

 

If these products are added in earnest, the share of biosimilars in the Avastin market is expected to rise further.

 

Mabthera biosimilars' share in the rituximab market increased from 8% in 2018 to 25% last year.

 

Currently, Celltrion's Truxima is sold alone.

 

Humira biosimilars recorded a 9% market share last year.

 

Samsung Bioepis released Adalloce in the third quarter of 2021, and Celltrion released Yuflyma in the third quarter of last year.

 

Sales last year were 7.6 billion won for Adaloch and 500 million won for Yuflyma.

 

Remicade biosimilars recorded a 38% market share last year.

 

Celltrion Remsima posted 29.3 billion won in sales last year, and Samsung Bioepis Remaloce posted 4.9 billion won in sales.

 

The original Remicade's sales are 55.5 billion won.